Blog

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

Jul 30 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA),a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announced it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin. “NOVA is developing a novel, proprietary…

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Jul 30 • 4 min read

Entheon Biomedical Corp. (CSE: ENBI) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs. Further to the Company’s…

Tryp Therapeutics Announces Q3 2021 Financial Results

Jul 29 • 3 min read

Quick Take: Tryp Therapeutics has announced their Q3 2021 financial results, stating $6.1 million in assets including $5.6 million in cash Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its interim financial results for…

Levitee Labs Announces Completion of Acquisition of BlockMD Telemedicine Platform

Jul 29 • 2 min read

Quick Take: Levitee Labs has acquired BlockMD, a telemedicine platform for patients with substance abuse disorders in western Canada. Levitee Labs Inc. (CSE: LVT) (the “Company” or “Levitee”), a biotechnology company with a diversified portfolio of healthcare and wellness assets, is pleased to announce that it has completed the acquisition of all the issued and outstanding shares of…

Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

Jul 29 • 2 min read

Quick Take: Cybin has recieved approval for its common shares to be listed on the NYSE around August 5th. Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for the listing of its common shares on the NYSE American LLC stock exchange (“NYSE American”). The Company…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548